Summary
Edwards Lifesciences (EW) filed an 8-K on October 27, 2022, to announce its financial results for the third quarter of 2022. The filing primarily consists of a press release that details the company's performance during the period. Investors should pay close attention to the revenue, earnings per share, and any forward-looking guidance provided in the press release for a comprehensive understanding of the company's current financial health and future outlook.
Key Highlights
- 1The 8-K filing includes a press release detailing Edwards Lifesciences' financial results for the third quarter of 2022.
- 2The press release, furnished as Exhibit 99.1, provides the company's reported financial performance for the Q3 2022 period.
- 3This filing serves as the official notification of the company's Q3 2022 financial outcomes.
- 4Investors can find specific details on revenue, profitability, and other key financial metrics within the referenced press release.
- 5The information furnished is not deemed 'filed' for purposes of the Securities Exchange Act of 1934, a standard disclosure for press release attachments.
- 6The event date and filing date are both October 26, 2022, indicating the results were released shortly after the reporting period concluded.